Blood Test Could Predict Alzheimer's 2-4 Years Early

Imagine knowing years in advance that someone you love might develop Alzheimer's, giving you time to plan, prepare, and possibly slow the disease. That future just got closer to reality.

Researchers funded by the National Institutes of Health have created an experimental blood test that predicts Alzheimer's symptoms 2 to 4 years before they start. The test analyzes circular RNAs in the blood, detecting brain changes earlier than any current diagnostic tool.

The study examined blood samples from more than 1,200 people and identified 34 circular RNAs linked to Alzheimer's disease. When researchers compared this new approach to existing tests that look for pTau217 protein, both methods equally identified people who already had Alzheimer's. But the circular RNA test did something better.

It successfully predicted which healthy people would later develop symptoms. Current blood tests can only detect protein markers linked to amyloid plaques, the sticky brain deposits associated with Alzheimer's, but they can't forecast when or if symptoms will appear.

Dr. Krishnankutty Sathian, chair of neurology at Penn State Health Milton S. Hershey Medical Center, calls this an "exciting development." Some people carry Alzheimer's markers their entire lives but never develop symptoms, thanks to cognitive reserve or brain resilience.

Dr. Clifford Segil, a neurologist at Providence Saint John's Health Center in Santa Monica, California, notes that most neurologists won't diagnose Alzheimer's from blood tests alone because they could create false positives. Nobody wants to tell someone they have dementia when they don't.

The Bright Side

The real gift of this test isn't just diagnosis. It's the window of time it creates for families and patients to act.

If validated through further research, the test could become part of routine preventive care for older adults or screening for high-risk individuals. Early detection means earlier access to new treatments that work best in the disease's initial stages. It gives families time to have important conversations, make financial plans, and build support systems while their loved one can still participate fully.

The scientists behind the test are already working with companies to develop versions for clinical use.

What started in a research lab could soon give millions of families something invaluable: time to prepare, time to treat, and time to hope.